Am J Blood Res 2011;1(2):135-145
Review Article
Progress in myeloma stem cells
Richard Dela Cruz, Guido Tricot, Maurizio Zangari, Fenghuang Zhan
Division of Hematology, Blood/Marrow Transplant and Myeloma Program, 30 N 1900 E, 5C417, University of Utah, Salt Lake
City, UT 84132, USA.
Received July 15, 2011; accepted July 31, 2011; Epub September 8, 2011; published September 30, 2011
Abstract: Multiple myeloma (MM) is the second most common hematologic malignancy in the United States and affects about
4 in 100,000 Americans. Even though much progress has been made in MM therapy, MM remains an incurable disease for
the vast majority of patients. The existence of MM stem cell is considered one of the major causes of MM drug-resistance,
leading to relapse. This highlights the importance and urgency of developing approaches to target MM stem cells. However,
very little is known about the molecular characteristics of the MM stem cells, which makes it difficult to target MM stem cells
therapeutically. Evidence of the existence of a myeloma stem cell has been provided by Matsui et al. showing that the CD138-
and CD20+ fraction, which is a minor population of the MM cells, has a greater clonogenic potential and has the phenotype of
a memory B-cell (CD19+, CD27+). In this review, we report recent progress of cell surface markers in cancer stem cells,
especially in myeloma and the molecular mechanisms related to drug resistance and myeloma disease progression.
(AJBR1107001).
Keywords: Cancer stem cell, multiple myeloma, drug resistance, and cell signaling
Full Text PDF
Address all correspondence to:
Fenghuang Zhan, MD, PhD
Division of Hematology, Blood/Marrow Transplant and Myeloma Program
University of Utah School of Medicine
30 N 1900 E, 5C417, Salt Lake City, UT 84132, USA.
E-mail: fenghuang.zhan@hsc.utah.edu
Review Article
Progress in myeloma stem cells
Richard Dela Cruz, Guido Tricot, Maurizio Zangari, Fenghuang Zhan
Division of Hematology, Blood/Marrow Transplant and Myeloma Program, 30 N 1900 E, 5C417, University of Utah, Salt Lake
City, UT 84132, USA.
Received July 15, 2011; accepted July 31, 2011; Epub September 8, 2011; published September 30, 2011
Abstract: Multiple myeloma (MM) is the second most common hematologic malignancy in the United States and affects about
4 in 100,000 Americans. Even though much progress has been made in MM therapy, MM remains an incurable disease for
the vast majority of patients. The existence of MM stem cell is considered one of the major causes of MM drug-resistance,
leading to relapse. This highlights the importance and urgency of developing approaches to target MM stem cells. However,
very little is known about the molecular characteristics of the MM stem cells, which makes it difficult to target MM stem cells
therapeutically. Evidence of the existence of a myeloma stem cell has been provided by Matsui et al. showing that the CD138-
and CD20+ fraction, which is a minor population of the MM cells, has a greater clonogenic potential and has the phenotype of
a memory B-cell (CD19+, CD27+). In this review, we report recent progress of cell surface markers in cancer stem cells,
especially in myeloma and the molecular mechanisms related to drug resistance and myeloma disease progression.
(AJBR1107001).
Keywords: Cancer stem cell, multiple myeloma, drug resistance, and cell signaling
Full Text PDF
Address all correspondence to:
Fenghuang Zhan, MD, PhD
Division of Hematology, Blood/Marrow Transplant and Myeloma Program
University of Utah School of Medicine
30 N 1900 E, 5C417, Salt Lake City, UT 84132, USA.
E-mail: fenghuang.zhan@hsc.utah.edu
| AJBR Copyright © 2011-present, All rights reserved. Published by e-Century Publishing Corporation, Madison, WI 53711, USA |
 |  |  |  |  |  |  |